Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
High today .026
Low .0146
Wild swings the last few days.
That is incorrect. CBLI is 39% of CYTO after the merger. So market cap of Cytocom will be around 230 million. IMUN owning 9% would be over 20 million. or around .045 cents a share.
LDN is currently being prescribed off label right now for crohns disease. It is effective and the level 3 trials should show great results!
The good news just keeps on coming!
Starting phase 3 trials for treating Chron's disease with an 11 Billion CRO is huge news!
In separate news, Cytocom has entered into an agreement with ICON plc (NASDAQ: ICLR), a global contract research organization (CRO), to manage its upcoming Phase 3 clinical trial for its lead drug candidate, CYTO-201, as a treatment for Crohn’s disease.
“We are pleased with the progress we are making in our CYTO-200 clinical program, which includes Phase 3-ready assets in Crohn’s disease, fibromyalgia and multiple sclerosis, as well as our COVID-19 therapy, CYTO-205,” stated Mr. Handley. “CYTO-201 is the program’s lead clinical asset and we are pleased to have ICON as our CRO partner given the company’s proven expertise and track record of clinical excellence. Meanwhile, with the filing of the Phase 2 IND for CYTO-205 in COVID-19 and corresponding manufacturing, we are steadily advancing our efforts to address the significant need for COVID-19 therapies.”
CYTO-200 Clinical Programs
The goals of the CYTO-200 programs are to treat patients by restoring immune homeostasis. Our clinical programs include CYTO-205 in COVID-19, and three Phase 3-ready development programs for the treatment of Crohn’s disease (CYTO-201), fibromyalgia (CYTO-202) and multiple sclerosis (CYTO-203).
I would agree with you that it will be valued much higher. Lets hope!
My calculations are IMUN should be valued at around 20 Million with Cbli being at 88 Million and only 40% of the combined company. 220 million company after merger at 9% is 19.8 million, Almost double current market cap. I have no idea if that is accurate but I would love the stock to be around .045
No idea, tomorrow there will probably be 125 posts because it went up then they will disappear again, but we keep moving steadily higher as it gets closer to the merger.
Moving on up!
Stock continues to move higher!!
The research report? I have no idea. I can't even figure out who follows CBLI. It says there is one analyst who covers
$40 price target and rated as a hold?? Maybe after the merger Cytocom will receive real analyst coverage.
Nobody even talking about it on IMUN board. Wish I owned more of this one. I own some but more IMUN. Hopefully that stock will pop too.
CBLI spiking up 30%, news coming???
CBLI current market cap at 61.4 million. That would price Cytocom after merger at over 150 Million. IMUN market cap should be around 14 million. Almost double where the stock is trading right now.
This stock is driving me nuts! Hopefully merger will go through 2nd quarter. They had hoped for 1st quarter.
Cytocom attending a conference next week.
Company merger between Cytocom and CBLI occurring by end of 1st quarter.
CBLI approaching $4.
IMUN is it time to get this party started!
Last two days have been pretty good for IMUN and CBLI. I think January will be interesting. Kind of nice not having the pumpers post 75 times in a day. Happy Holidays! Hope we all get rich in 2021.
This is all I've found:
Cleveland BioLabs (NASDAQ:CBLI) stock moved upwards by 26.4% to $3.59. This security traded at a volume of 749.4K shares come close, making up 29.52% of its average volume over the last 100 days. The market value of their outstanding shares is at $46.7 million.
Just saw that wonder why??
Reason why might be because its not specifically Londonal. However, I agree a PR and explaining what this means for Cytocom/IMUN/Londonal, where exactly they are in trials would for sure improve stock price. So much shareholders are in the dark on. Hopefully, we will hear something more in December.
I know that LDN is already being prescribed by doctors already for Chron's. It is inexpensive and patients are having get results with very few side effects.
I wonder if that means some news is coming that they think CYTO will be able to list on the Nasdaq after merger at 160 million valuation.
On Cytocom website is says they will be hosting another conference call in December.
CBLI has been moving up since the announcement of the merger. I think that is good news for IMUN as well.
I agree with this. I would have been very surprised to here about IMUN stake. Overall the call was a positive. Yes, for CYTO it is more of a longer term pipeline story and some of us have been waiting for a long time, but becoming a company listed on the Nasdaq is a huge step in the right direction for both Cyctocom and IMUN IMO. There could be some stock price improvement too in short term if trials start for COVID this year or Chron's next quarter. I am also hopeful that IMUN will work on their own pipeline development. Hopefully, we hear something soon.
IMUn should still own somewhere around 9% of Cytocom after the merger. It seems a little murky as there is also the acquisition of Imquest. I'm not sure if that dilutes the % of Cyctocom IMUN owns. Very unclear through conference call.
I'm hopeful that IMUN will hold their own conference call in the next few weeks to clarify their relationship with CYTO and plans for the future for IMUN. Right now IMUN is really just a shell company which can be fine if they have other things in the works.
Not a bad idea!
Doctor suggesting giving President Trump LDN to build up Immunity against COVID. Mentioned at 9 minutes 26 seconds
What is the company's forward looking transition strategy? What do they have besides a 15% stake in Cyctocom? If it is true that it was too expensive and not profitable enough to proceed with LDN in emerging markets then great we got rid of 5 million dollars in financial obligations. What is the plan going forward? Do they have one?
Hopefully because LDN will be a big money maker and we still own 15% of Cyctocom so we will get a piece of the action.
On July 22, 2020, director Kevin J. Phelps, interim president and CEO of Immune Therapeutics, Inc. (“Immune” or the “Company”) entered into a three-year executive employment agreement (the “Agreement”) with the Company to serve as president and CEO. This agreement was formally approved by the Company’s Board as of July 24, 2020 with Mr. Phelps abstaining. While fully effective, the parties may expand and restate the Agreement within thirty days
Any possibility that this deal will dilute our 15% ownership in Cyctocom? I would imagine IMUN would have to put out a press release if that were the case?
Rough start today. Who knows not very high volume.
Have to say, I'm happy with the way stock is moving. .029 and no one on this board at least pumping the stock. Probably a good sign that the buyers are more long term and not looking to flip.
I agree why would IMUN do an RS when all they really have is 15% ownership of a drug not currently bringing in any revenue. I would hope the RS is still on the table, because they are looking to do a merger with another company that has a pipeline of drugs to offer. Unless a huge blockbuster pet food deal is about to happen haha!
Told you so! Wish you the best of luck. Your cost basis is lower than mine.
Hey, I'm getting almost to break even on this stock!! Been a long road.
IDK I used to be a broker about 20 years ago. If I had more clients with 10 million invested in the market I still would be. The investor says hey I've heard about LDN I want to get into this stock for about 100k. See how much you can buy today going not higher then .02. Okay sounds great, I'll keep you updated and see what I can do. Your average cost is .0167 and it closed at .019. Sounds great thank you very much have a great weekend!
I hope your insider info and big news coming next week is the real reason and not mine.